Cell Biosciences and Alpha Innotech have entered an agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for USD1.50 (GBP0.91) per share or approximately USD17.9m in cash.
This acquisition will expand Cell Biosciences' protein-analysis business to include a global infrastructure and a broad protein-analysis product portfolio.
Alpha Innotech uses high-sensitivity digital imaging systems for genomic and proteomic research.
Its products include entry-level gel documentation systems to premier systems for multiplexed fluorescence and proteomics applications.
The company has sold more than 10,000 systems worldwide.
In 2008, Alpha Innotech achieved revenues of USD17.9m and was profitable on both an operating and a net-income basis.
Cell Biosciences is a private life-sciences company that is focused on revolutionising protein and biomarker research.
The completion of the transaction is subject to customary terms and conditions, including approval by the stockholders of Alpha Innotech.
